|
Therapy Area
Treatment of hepatitis C virus (HCV) infection.
|
|
Phase
Phase I studies completed and reported. Phase IIa studies in patients are ongoing. Phase IIb studies to be initiated. |
Competitive Edge
Novel HCV NS3/4A protease inhibitor with excellent antiviral activity in HCV infected patients. PK profile supporting a once-daily dosing. |
Project data
- Collaboration with Tibotec since 2004
- Phase IIa studies ongoing
- Excellent antiviral activity in HCV infected patients
- PK profile supporting a once-daily dosing
- Several series of potent inhibitors have been developed that provide backups
|
|
|
|
|
|
